Navigation Links
Drug treatment improves learning in mice with Down syndrome symptoms, Stanford/Packard study shows

A once-a-day, short-term treatment with a drug compound substantially improved learning and memory in mice with Down syndrome symptoms, say researchers at the Stanford University School of Medicine and Lucile Packard Children’s Hospital. What’s more, the gains lasted for months after the treatment was discontinued. The researchers are now considering a clinical trial to test whether the compound has a similar effect in humans with Down syndrome.

"This treatment has remarkable potential," said Craig Garner, PhD, professor of psychiatry and behavioral sciences and co-director of Stanford’s Down Syndrome Research Center. "So many other drugs have been tried that had no effect all. Our findings clearly open a new avenue for considering how cognitive dysfunction in individuals with Down syndrome might be treated." The center was created by researchers at Stanford and Packard Children’s in 2003 to rapidly translate research discoveries into useful treatments for people with Down syndrome.

The research, which will be published Feb. 25 in the advance online edition of Nature Neuroscience, was conducted by Fabian Fernandez, a graduate student in Garner’s laboratory. Fernandez found that affected mice were significantly better able to identify novel objects and navigate a maze ­ tasks that simulate difficulties faced by children and adults with Down syndrome ­ after being fed 17 daily doses of milk containing a compound called pentylenetetrazole, or PTZ. Treated mice performed as well as their wild-type counterparts for up to two months after drug treatment was discontinued.

"Somehow the drug treatment creates a new capacity for learning," said Garner, who cautions that this new ability may decay over longer periods of time as older, drug-experienced neurons are replaced by younger cells.

The researchers believe that the key to the improvement lies in the fact that PTZ blocks the action of an inhibitory neurotransmitter called GABA. Normal brains maintain a precise ratio between neuronal excitation and inhibition that allows efficient learning. In contrast, it’s thought that Down syndrome patients have too much GABA-related inhibition, making it difficult to process information.

"In general, learning involves neuronal excitation in certain parts of the brain," said Garner. "For example, caffeine, which is a stimulant, can make us more attentive and aware, and enhance learning. Conversely, alcohol or sedatives impair our ability to learn."

But as any overenthusiastic college student can attest, too much caffeine can backfire. The same is true with high doses of PTZ, which can cause seizures. In fact, after some brief, inconclusive studies on cognition enhancement in elderly or mentally impaired people in the 1950s, PTZ has been primarily used for the study of epilepsy in animals. In 1982 the FDA withdrew approval for the use of PTZ in humans because no clear clinical benefit had been established. That is, until now.

"My idea was that it might be possible to harness this excitation effect, which at higher doses can be pathological, to benefit people with Down syndrome," said Fernandez.

More than 300,000 people nationwide have Down syndrome, which is caused by an extra copy of chromosome 21. It is the leading cause of mental retardation in the country, and it is also associated with childhood heart disease, leukemia and early onset Alzheimer’s disease. The researchers used a mouse model of Down syndrome for their study in which about 150 genes are triplicated. The mice exhibit many of the cognitive problems that afflict human Down syndrome patients.

Fernandez gave low daily doses of PTZ and investigated the animals?responses to unfamiliar objects and a T-shaped maze. In the first example, he allowed the animals to explore two similarly sized, yet obviously different, objects for 15 minutes. Twenty-four hours later he exposed the same animals to one of th e previously seen objects and a third, never-before-seen object. Although wild-type mice spent more time investigating the new object, untreated Down syndrome mice showed no preference for either object.

In the maze test, mice were habituated to the long arm of a T-shaped maze and then allowed to explore. Wild-type mice tended to investigate first one, then the other arm of the maze, while untreated Down syndrome mice were less methodical. However, the Down syndrome mice performed more like their wild-type counterparts on both tests after 17 days of PTZ treatment.

The researchers discovered two interesting things when testing the mice: daily doses were required for several days before any effect was detected, and, once established, the effect lasted for up to two months after the drug was withdrawn. In fact, the drug’s activity profile mirrored that of some well-known psychiatric medications.

"This suggests that it’s not just the removal of the excess inhibition that allows learning to occur, but that we’re instead strengthening synapses through some type of long-lasting neuronal adaptation," said Garner.

A key component of enduring neural change associated with memory is known as long-term potentiation. In general terms, once a threshold of activating signals has been achieved, a neuron becomes permanently more sensitive to excitation. Although long-term potentiation has been shown to be impaired or absent in the brains of Down syndrome mice, postdoctoral scholar Wade Morishita, PhD, who works in the Stanford laboratory of professor Rob Malenka, PhD, found that it approached normal levels after chronic PTZ treatment and remained comparable to that in wild-type mice for up to three months after PTZ was discontinued.

PTZ’s history of use in humans is an advantage when planning a clinical trial. However, the compound is not currently approved by the Food and Drug Administration for use in humans. Garner and Fernandez b oth strongly cautioned individuals against experimenting with the compound or others like it on their own. Appropriate doses and schedules have not yet been determined for humans, and the purity and safety of similar over-the-counter concoctions are questionable. Finally, they emphasized that PTZ treatment did not improve the learning capabilities of normal mice.

"We’re not in the business of cognitive enhancement," said Fernandez. "Basically, we have something that could be one part of the many different medical and environmental interventions that may allow kids with Down syndrome to live more normally."

Source:Stanford University Medical Center

Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
4. Researchers add new tool to tumor-treatment arsenal
5. Potential treatments for neurofibromatosis
6. Nanoparticles offer new hope for detection and treatment
7. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
8. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
9. New understanding of DNA repair may pave way to cancer treatments
10. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
11. Newer imaging techniques may lead to over-treatment

Post Your Comments:

(Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology: